AEON Biopharma宣布,公司已就ABP-450生物类似药项目完成与美国食品药品监督管理局(FDA)的B类2a型会议,并获得了监管机构的正式反馈意见。
AEON Biopharma宣布,公司已就ABP-450生物类似药项目完成与美国食品药品监督管理局(FDA)的B类2a型会议,并获得了监管机构的正式反馈意见。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.